




Profile

- Critical Outcome Technologies Inc. (COTI) is a clinical stage biotech company focused on the development of novel therapeutics for the treatment of cancers and other unmet medical needs.
- COTI has a pipeline of internally developed compounds. Its lead clinical candidate, COTI-2, is currently in an open label, multi-site Phase I trial in gynecological malignancies. Its second lead clinical candidate, COTI-219, is currently in IND-enabling studies.
- COTI's CHEMSAS® platform is a computational high-throughput screening technology for molecule identification.
- COTI's ROSALIND™ technology is a genomics profiling platform for personalized oncology care.
- COTI has offices in Ontario, Canada and in Boston, Massachusetts.

WHAT IS CHEMSAS®?

- Computerized Hybrid Expert Molecular Structure Activity Screening (CHEMSAS) is a drug discovery and preclinical development engine using a core platform technology.
- It uses machine learning software and proprietary algorithms in a novel and proprietary process.
- CHEMSAS accelerates drug discovery and provides optimized lead compounds with a higher probability of clinical success.
- There are six major stages of the CHEMSAS technology (Figure 1).

Figure 1. A simplified representation of CHEMSAS.



WHAT IS ROSALIND™?

- ROSALIND is a smart data platform that evaluates a tumor's specific gene mutation profile and identifies treatments most likely to restore normal cell signaling (Figure 2).
- Tumors have millions of mutation profiles, which allow for thousands of drug combinations. The vast combinations of drugs are too much for any clinician to consider.
- ROSALIND provides physicians with suggestions of treatment combinations most likely to be effective against the specific mutation profile of the tumor.

Figure 2. A brief overview of ROSALIND.

